RBTQ Stock Chart & Stats
€2.04
-€0.08(-4.42%)
At close: 4:00 PM EST
€2.04
-€0.08(-4.42%)
Day’s Range― - ―
52-Week Range€1.13 - €2.56
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€59.14M
Enterprise Value€51.17M
Total Cash (Recent Filing)€10.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 07, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.39Price Target Upside801.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA near-zero debt position and roughly $12.4M of equity materially reduce solvency and interest-rate exposure, giving management flexibility to fund development through equity or partnerships. This durable strength lowers short-term default risk and supports longer runways versus leveraged peers.
Supportive Exploratory Clinical SignalPositive exploratory ARDS/kidney outcomes for the anti-TLR4 antibody substantiate the biological rationale and may de-risk target validation. If confirmed in follow-up trials, this durable clinical signal could broaden indications, inform trial design, and increase the asset's licensing or partnering appeal.
Insider-led PIPE Increases Runway And AlignmentA $3.5M insider-led private placement signals management and investor conviction while providing incremental funding to progress key programs. Insider participation aligns incentives and extends near-term development runway, reducing immediate solvency pressure and enabling continued clinical advancement.
Bears Say
Minimal Commercial RevenueThe company remains pre-revenue with negligible product sales, meaning long-term viability depends on clinical success, partnering, or continued financings. Without commercialization, persistent lack of recurring revenue is a structural weakness for sustaining R&D and operations over the medium term.
Sustained Cash Burn And Negative Cash FlowMaterial negative operating and free cash flow reflect ongoing cash burn typical of development-stage biotech. Over 2–6 months this cash profile requires fresh capital, constrains strategic optionality, and can force accelerated partnering or asset sales if financing windows narrow.
Dependence On Equity Financings (dilution Risk)Frequent equity issuances, expanded incentive share capacity, and large insider-led placements indicate reliance on dilutive financing to fund operations. This structurally raises shareholder dilution risk, can compress per-share economics, and ties the company's runway to capital-market access rather than operating cash generation.
Edesa Biotech News
RBTQ FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was €1.13 and its highest was €2.56 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is €59.14M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 26 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -€0.429 earnings per share for the quarter, missing the consensus estimate of -€0.228 by -€0.201.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.38.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 9,633,223 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -€0.429 in its last earnings report, missing expectations of -€0.228. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in DE:RBTQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.39 (801.56% Upside)
€18.39 (801.56% Upside)
Blogger Sentiment
Bullish
DE:RBTQ Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
238.64%
12-Months-Change
Fundamentals
Return on Equity
-82.34%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
RBTQ Stock 12 Month Forecast
Average Price Target
€18.39
▲(801.56% Upside)
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Options Prices
Currently, No data available
---